This message contains images. If you don't see images, click here to view.
Advertise in this news brief.



Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit |  Histology Marketplace:     

Home   History   Meeting Calendar   Career Center   Certification   Contact Us    



 




NSH NEWS

Annual International Pathology Day – Nov. 5
NSH
Today is the first International Pathology Day! Celebrate pathologists, laboratory scientists and institutions/organizations around the world that have the same passion as you! Thank them for the hard work they do each and every day and most of all, help the public understand the important role of pathology in their daily lives. Learn more.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




US certification eligibility requirement revisions and new international certification eligibility requirements
NSH
The Board of Certification Board of Governors met on Oct. 11-12 in Tampa, Florida. A number of actions were taken at this meeting that include important information for histology professionals. Click here for more details.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


SPONSORED CONTENT


TOP STORIES


Clues to more deadly thyroid cancers discovered
St. Petersburg Tribune
Over the last 30 years or so, the incidence of thyroid cancer in the United States has risen threefold, making it the country's most rapidly increasing form of malignancy. Fortunately, most thyroid cancers are slow growing and as a result can be controlled with a combination of surgery and treatments with thyroid hormone and radioactive iodine. There are, however, more aggressive forms of thyroid cancer that require more intensive treatments. Researchers with a federally funded program that looks at cancers at the genetic level say they have found clues that should help doctors discover which thyroid cancers are potentially more deadly and pave the way for more effective treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  GBI Cost Effective Products

GBI Labs produces the largest selection of secondary detection kits, from single to multiple detection kits, with wide range host species. We provide FREE samples to 1st time users. Staining with our kits results in similar or better sensitivity than other detection kits on the market with 20%-30% cost less.
 


Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice
Nature Biotechnology
Gram-positive bacterial pathogens that secrete cytotoxic pore-forming toxins, such as Staphylococcus aureus and Streptococcus pneumoniae, cause a substantial burden of disease. Inspired by the principles that govern natural toxin-host interactions, we have engineered artificial liposomes that are tailored to effectively compete with host cells for toxin binding.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Narrow networks mean shrinking opportunity for pathology and clinical medical labs
Dark Daily
Insurers are increasingly using narrow networks as a business strategy to control costs. As a consequence, more consumers are complaining even as some excluded providers are suing health insurers. For pathologists and clinical laboratory managers, this accelerating trend of excluding providers means increasingly restricted access to patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Assessing the science of Ebola transmission
The Atlantic
As leading Ebola virologist Heinz Feldmann recently said, the discussion of Ebola prevention "should be fact-based; it should be data-based." Interpretation of those facts and data is often clouded by politics and opinion. But they are not as ambiguous as debates in media have made them seem. Recently, The Atlantic ran an interview on the current Ebola epidemic with Steven Hatfill, a former employee of the U.S. Army Medical Research Institute of Infectious Disease who is famous for being wrongly accused of the 2001 anthrax attacks. Hatfill, presented as a world-leading expert on Ebola virus, gave his perspective on topics ranging from transmission of the virus to preparedness for an outbreak in the United States.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


IN THE NEWS


Improving imaging of cancerous tissues by reversing time
Lab Manager
As children, it was fascinating to put a flashlight up to our palms to see the light shine through the hand. Washington University in St. Louis engineers are using a similar idea to track movement inside the body's tissues to improve imaging of cancerous tissues and to develop potential treatments.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


2 days of chemotherapy drug may control immune disease post-transplant
By Lynn Hetzler
A short course of a chemotherapy drug may control life-threatening immune response, according to a new study, and even eliminate transplant patients' need for six months of immune suppression therapy. Patients receive a two-day course of cyclophosphamide after bone marrow transplant surgery in addition to receiving two other chemotherapy drugs before surgery. Researchers from Johns Hopkins described their latest results online in the Journal of Clinical Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Modeling Ebola in mice
The Scientist
Researchers investigating host responses to Ebola have long faced a significant disadvantage: the virus kills conventional lab mice, but does not produce the hemorrhagic fever or other classical symptoms that occur in humans. The lack of a mouse disease model has hampered studies on the pathology and immunology of Ebola infections, as well as the development of treatments.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


How a gene-patent test case will help both patients and inventors
The Globe and Mail
Canadian prosperity depends on our ability to innovate. When it comes to unlocking the power and mysteries of genomic medicine, our competitors in the United States now have free reign — but Canadian innovators continue to be shackled. The Children's Hospital of Eastern Ontario launched a test case against human gene patents recently. The primary objective of the case is to ensure that CHEO patients — children with a potentially lethal yet often otherwise undetectable disease — receive the health care they need. A parallel objective of the case is to address long-standing problems with gene patents that hamper rather than enable innovators.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    NSH webinar: The Magical Science of Rubrics — Nov. 5 (NSH)
Here's what would happen if Ebola was stolen from a lab (TIME)
'Genetic Testing Handbook' provides pathologists, lab managers with comprehensive reference for clinical genome and exome sequencing (Dark Daily)
Cigna sues Virginia clinical lab for $84 million (Hartford Courant)

Don't be left behind. Click here to see what else you missed.


 

Under the Microscope
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642   
Contribute news

This edition of Under the Microscope was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Oct 30, 2014 Blast
Oct. 29, 2014
Oct. 22, 2014
oct 16, 2014 Blast



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063